Comparative overview of major clinical trials in MM
| Trial name . | Study population . | Treatment arm . | Control arm . | Primary end point . | PFS, mo . | OS, mo . | Key finding . | Reference . |
|---|---|---|---|---|---|---|---|---|
| CASSIOPEIA | NDMM, transplant-eligible | Dara-VTd | VTd | sCR rate | 57.6 | Not reached | Dara-VTd improved depth of response, increased stringent CR rate, and prolonged PFS over VTd. | 16 |
| GRIFFIN | NDMM, transplant-eligible | Dara-VRd | VRd | sCR Rate | 48.7 | Not reached | Dara-VRd significantly increased MRD-negative rates and improved PFS compared to VRd. | 17 |
| ICARIA-MM | R/R MM, lenalidomide-refractory | Isa-Pd | Pd | PFS | 11.5 | 17.4 | Isatuximab + Pd improved PFS and OS over Pd alone in lenalidomide-refractory MM. | 18 |
| POLLUX | R/R MM | Dara-Rd | Rd | PFS | 44.5 | Not reached | Dara-Rd significantly improved PFS and response rates, establishing Dara-Rd as a preferred regimen. | 19 |
| MagnetisMM-3 | R/R MM, triple-class refractory | Elranatamab (BsAb) | N/A | ORR | 17.2 | Not reached | Elranatamab, a BCMA/CD3 bispecific antibody, showed durable responses in heavily pretreated patients with R/R MM. | 20 |
| KarMMa-1 | R/R MM, triple-class refractory | Ide-cel (CAR-T) | N/A | ORR | 8.8 | 24.8 | Ide-cel demonstrated deep and durable responses in heavily pretreated patients with R/R MM. | 21 |
| CARTITUDE-1 | R/R MM, triple-class refractory | Cilta-cel (CAR-T) | N/A | ORR | 33 | Not reached | Cilta-cel achieved high ORR and deep responses, with superior survival benefits over standard care. | 22 |
| MajesTEC-1 | R/R MM, triple-class refractory | Teclistamab (BsAb) | N/A | ORR | 11.3 | Not reached | Teclistamab, a BCMA/CD3 bispecific antibody, showed promising efficacy in heavily pretreated patients with R/R MM. | 23 |
| Trial name . | Study population . | Treatment arm . | Control arm . | Primary end point . | PFS, mo . | OS, mo . | Key finding . | Reference . |
|---|---|---|---|---|---|---|---|---|
| CASSIOPEIA | NDMM, transplant-eligible | Dara-VTd | VTd | sCR rate | 57.6 | Not reached | Dara-VTd improved depth of response, increased stringent CR rate, and prolonged PFS over VTd. | 16 |
| GRIFFIN | NDMM, transplant-eligible | Dara-VRd | VRd | sCR Rate | 48.7 | Not reached | Dara-VRd significantly increased MRD-negative rates and improved PFS compared to VRd. | 17 |
| ICARIA-MM | R/R MM, lenalidomide-refractory | Isa-Pd | Pd | PFS | 11.5 | 17.4 | Isatuximab + Pd improved PFS and OS over Pd alone in lenalidomide-refractory MM. | 18 |
| POLLUX | R/R MM | Dara-Rd | Rd | PFS | 44.5 | Not reached | Dara-Rd significantly improved PFS and response rates, establishing Dara-Rd as a preferred regimen. | 19 |
| MagnetisMM-3 | R/R MM, triple-class refractory | Elranatamab (BsAb) | N/A | ORR | 17.2 | Not reached | Elranatamab, a BCMA/CD3 bispecific antibody, showed durable responses in heavily pretreated patients with R/R MM. | 20 |
| KarMMa-1 | R/R MM, triple-class refractory | Ide-cel (CAR-T) | N/A | ORR | 8.8 | 24.8 | Ide-cel demonstrated deep and durable responses in heavily pretreated patients with R/R MM. | 21 |
| CARTITUDE-1 | R/R MM, triple-class refractory | Cilta-cel (CAR-T) | N/A | ORR | 33 | Not reached | Cilta-cel achieved high ORR and deep responses, with superior survival benefits over standard care. | 22 |
| MajesTEC-1 | R/R MM, triple-class refractory | Teclistamab (BsAb) | N/A | ORR | 11.3 | Not reached | Teclistamab, a BCMA/CD3 bispecific antibody, showed promising efficacy in heavily pretreated patients with R/R MM. | 23 |
Cilta-cel (CAR-T), ciltacabtagene autoleucel; CR, complete response; Dara-VTd, daratumumab + VTd; Dara-VRd, daratumumab + VRd; Dara-Rd, daratumumab + lenalidomide, dexamethasone; Elranatamab (BsAb), BCMA/CD3 bispecific antibody; Isa-Pd, isatuximab + pomalidomide, dexamethasone; Ide-cel (CAR-T), idecabtagene vicleucel (CAR-T); N/A, not applicable; ORR, overall response rate; sCR, stringent complete response; Teclistamab (BsAb), BCMA/CD3 bispecific antibody; VTd, bortezomib, thalidomide, dexamethasone.